LONGEVERON INC-A (LGVN) Stock Price, Forecast & Analysis
NASDAQ:LGVN • US54303L2034
LGVN Key Statistics, Chart & Performance
The current stock price of LGVN is 0.5358 USD. In the past month the price decreased by -5%. In the past year, price decreased by -67.92%.
LGVN Technical Analysis
LGVN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LGVN. The financial health of LGVN is average, but there are quite some concerns on its profitability.
LGVN Financial Highlights
Over the last trailing twelve months LGVN reported a non-GAAP Earnings per Share(EPS) of -1.49. The EPS increased by 76.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -137.18% | ||
| ROE | -214.14% | ||
| Debt/Equity | 0 |
LGVN Forecast & Estimates
8 analysts have analysed LGVN and the average price target is 7 USD. This implies a price increase of 1206.41% is expected in the next year compared to the current price of 0.5358.
For the next year, analysts expect an EPS growth of 64.14% and a revenue growth -47.8% for LGVN
LGVN Ownership
LGVN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 402.079B | ||
| AMGN | AMGEN INC | 16.38 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 117.985B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.174B | ||
| BIIB | BIOGEN INC | 12.92 | 28.692B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LGVN
Company Profile
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 25 full-time employees. The company went IPO on 2021-02-12. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The firm is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Company Info
LONGEVERON INC-A
1951 NW 7th Ave, Ste 520
Miami FLORIDA 33136 US
CEO: Geoff Green
Employees: 25
Phone: 13053027158
LONGEVERON INC-A / LGVN FAQ
What does LONGEVERON INC-A do?
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 25 full-time employees. The company went IPO on 2021-02-12. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The firm is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Can you provide the latest stock price for LONGEVERON INC-A?
The current stock price of LGVN is 0.5358 USD. The price increased by 0.3% in the last trading session.
Does LONGEVERON INC-A pay dividends?
LGVN does not pay a dividend.
How is the ChartMill rating for LONGEVERON INC-A?
LGVN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for LONGEVERON INC-A?
LONGEVERON INC-A (LGVN) currently has 25 employees.
What is the ownership structure of LONGEVERON INC-A (LGVN)?
You can find the ownership structure of LONGEVERON INC-A (LGVN) on the Ownership tab.
What is the outstanding short interest for LONGEVERON INC-A?
The outstanding short interest for LONGEVERON INC-A (LGVN) is 6.5% of its float.